InnovoSIL-1 Antimicrobial Silver Shown to Kill COVID-19, Norovirus and Other Medically Important Viruses

June 18, 2024 at 20:00 PM EDT

Edmonton, 18 June 2024 – TheNewswire – Innovotech Inc. (TSX-V: IOT) reports the publication of “Antiviral Activity of Ag5IO6, A Unique Silver Compound” in the Special Issue of Viruses entitled “Impact of Co-Infections in COVID-19: Predisposing Mechanisms and Interplay between Invasive Viral, Bacterial, and Fungal Pathogens” (Viruses 2024, 16(6), 959, https://doi.org/10.3390/v16060959).

The reported study shows that Innovotech’s InnovoSIL™-1 silver periodate, originally developed for its broad-spectrum antimicrobial activity, including antibiofilm activity, has demonstrated rapid virucidal activity against norovirus and two strains of the SARS-CoV-2 virus.

In vitro testing following ASTM E1052-20 (Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension), showed that InnovoSIL™-1 silver was able to generate total kill of the omicron strain of COVID-19 within 30 minutes, as well as total kill of murine norovirus and the original COVID-19 strain within four hours.

Based on its performance in this study, it is anticipated that InnovoSIL™-1 silver would also be effective against viruses such as influenzas, herpes simplex virus 1 (HSV-1), and respiratory syncytial viruses (RSVs). The study showed low activity against adenovirus and no measurable antiviral activity against poliovirus.

InnovoSIL™-1 silver’s antiviral properties are broadly efficacious in wound dressings and medical devices, as well as new potential applications, such as coatings on touch surfaces or incorporation into air filters. In addition, these properties uniquely position InnovoSIL™-1 silver for situations where either infection prevention or simultaneous treatment of microbes (bacteria or fungi) and viruses are desirable.

Innovotech would like to acknowledge Alberta Innovates’ support for this research through an AICE-Validates grant.

About InnovoSIL™-1 Antimicrobial Silver

InnovoSIL™-1 antimicrobial silver possesses exceptional properties for efficacy against microbial biofilms, as well as long-term broad spectrum anti-adherence activity. It is simple to coat onto or incorporate into medical devices, with favorable release characteristics. Its unique structure limits its inactivation by bodily fluids. Combining silver and iodine increases its antimicrobial mechanisms of action, reducing the likelihood of a target developing resistance to it. InnovoSIL™-1 antimicrobial silver has demonstrated excellent stability under a wide variety of conditions and can be easily synthesized with high purity in a form that is simple to deposit onto metals or incorporate into wound dressings, gels, or polymers. Innovotech is presently working with a number of industry collaborators who are pursuing a variety of applications for InnovoSIL™-1 antimicrobial silver.

About Innovotech Inc:

Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology and can be found online at www.innovotech.ca.

Patricia Nadworny, Ph.D., B.Sc., P.Eng.

Chief Scientific Officer Innovotech Inc.

+780-448-0585x7 partricia.nadworny@innovotech.ca

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###